MEDI0382, a GLP ‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study

British Journal of Clinical Pharmacology, EarlyView.

Source: British Journal of Clinical Pharmacology - August 8, 2018 Category: Drugs & Pharmacology Authors: Philip D.Ambery , SebastianKlammt , Maximillian G.Posch , MarcellaPetrone , WenjiPu , CristinaRondinone , LutzJermutus , BoazHirshberg Source Type: research